Literature DB >> 10970677

Higher natural killer cell activity in schizophrenic patients: the impact of serum factors, medication, and smoking.

G Yovel1, P Sirota, D Mazeh, G Shakhar, E Rosenne, S Ben-Eliyahu.   

Abstract

Schizophrenia has been associated with altered immunity and reduced occurrence of autoimmune diseases and malignancies. A few studies in schizophrenic patients have assessed natural killer cell activity (NKA), but no consistent findings have emerged. However, NKA was assessed using standard procedures and in the absence of autologous serum and the various cytokines that modulate NKA and appear to be abnormal in schizophrenic patients. In the current study, therefore, the number of NK cells and the activity of the individual NK cell were assessed in whole blood shortly after blood withdrawal, in both the presence and the absence of autologous serum. Twenty-nine schizophrenic patients (11 nonmedicated), 8 nonschizophrenic control patients (bipolar and personality disorders), and 31 age-matched healthy controls were studied. Schizophrenic patients showed higher NKA per NK cell than controls and nonschizophrenic patients. This difference remained significant even when the nonmedicated schizophrenics, who showed the highest levels of NKA, were excluded. However, the increase in NKA was more pronounced in the presence of serum and was reduced to an insignificant level when serum was removed from the same samples. In both schizophrenic patients and controls, smokers and women showed lower NKA. Numbers of NK cells did not differ among groups, although medication affected blood concentration of other leukocytes. These findings indicate that the effects of serum factors, psychiatric medication, gender, and smoking should be considered when assessing NKA in schizophrenic patients. The observed higher NKA may help explain the surprising reports of low incidence of lung cancer and other malignancies in schizophrenic patients, despite their higher rate of smoking. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10970677     DOI: 10.1006/brbi.1999.0574

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  20 in total

Review 1.  Biobehavioral outcomes following psychological interventions for cancer patients.

Authors:  Barbara L Andersen
Journal:  J Consult Clin Psychol       Date:  2002-06

2.  Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

Authors:  Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

3.  Cancer incidence in young and middle-aged people with schizophrenia: nationwide cohort study in Taiwan, 2000-2010.

Authors:  L Y Chen; Y N Hung; Y Y Chen; S Y Yang; C H Pan; C C Chen; C J Kuo
Journal:  Epidemiol Psychiatr Sci       Date:  2016-11-21       Impact factor: 6.892

4.  Impaired neuroendocrine and immune response to acute stress in medication-naive patients with a first episode of psychosis.

Authors:  Janine A E M van Venrooij; Sjoerd B A H A Fluitman; Jeroen G Lijmer; Annemieke Kavelaars; Cobi J Heijnen; Herman G M Westenberg; René S Kahn; Christine C Gispen-de Wied
Journal:  Schizophr Bull       Date:  2010-06-17       Impact factor: 9.306

Review 5.  Behavioral genetics of the depression/cancer correlation: a look at the Ras oncogene family and the 'cerebral diabetes paradigm'.

Authors:  Janet K Brewer
Journal:  J Mol Neurosci       Date:  2008-06-18       Impact factor: 3.444

6.  Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability.

Authors:  Katherine E Burdick; Pamela DeRosse; John M Kane; Todd Lencz; Anil K Malhotra
Journal:  Am J Psychiatry       Date:  2010-01-15       Impact factor: 18.112

7.  Altered gene expression and function of peripheral blood natural killer cells in children with autism.

Authors:  Amanda M Enstrom; Lisa Lit; Charity E Onore; Jeff P Gregg; Robin L Hansen; Isaac N Pessah; Irva Hertz-Picciotto; Judy A Van de Water; Frank R Sharp; Paul Ashwood
Journal:  Brain Behav Immun       Date:  2008-08-14       Impact factor: 7.217

8.  Schizophrenia and Epigenetic Aging Biomarkers: Increased Mortality, Reduced Cancer Risk, and Unique Clozapine Effects.

Authors:  Albert T Higgins-Chen; Marco P Boks; Christiaan H Vinkers; René S Kahn; Morgan E Levine
Journal:  Biol Psychiatry       Date:  2020-02-08       Impact factor: 13.382

Review 9.  Autoimmunity in autism.

Authors:  Amanda M Enstrom; Judy A Van de Water; Paul Ashwood
Journal:  Curr Opin Investig Drugs       Date:  2009-05

Review 10.  The immunogenetics of neurological disease.

Authors:  Maneesh K Misra; Vincent Damotte; Jill A Hollenbach
Journal:  Immunology       Date:  2017-12-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.